- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Second-line squamous cell oesophageal carcinoma
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 464KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 86KB)
Nivolumab – March 2022
Nivolumab (Second-line squamous cell oesophageal carcinoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
Last updated
1 July 2022